Physician profile
Michael A Diamond
NPI 1174697569
$2,494.17
in general payments reported to CMS, 2019-2025
17 companies · $124 in 2025
The $124 reported for 2025 was less than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $711 · 2020: $444 · 2021: $251 · 2022: $186 · 2023: $310 · 2024: $470 · 2025: $124.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $903.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $903.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $810.39 | 2019-2025 | Airsupra, Farxiga, Fasenra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $393.24 | 2019-2021 | |
| Abbvie INC. | $292.97 | 2021-2023 | Ubrelvy, Qulipta |
| Amarin Pharma, INC. | $272.06 | 2019-2021 | |
| Lilly USA, LLC | $206.36 | 2019-2022 | |
| Novo Nordisk INC | $124.99 | 2022 | |
| Allergan, INC. | $104.69 | 2019-2020 | |
| Amgen INC. | $55.23 | 2019-2025 | Repatha, Otezla |
| Blueprint Medicines Corporation | $49.90 | 2024 | Ayvakit |
| Glaxosmithkline, LLC. | $37.16 | 2019-2025 | Shingrix, Arexvy |
| Jazz Pharmaceuticals INC. | $24.70 | 2024 | |
| Genentech USA, INC. | $23.12 | 2019 | |
| Pfizer INC. | $22.76 | 2023 | |
| Janssen Biotech, INC. | $20.25 | 2023 | Erleada |
| Tesaro, INC. | $19.73 | 2019 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $18.45 | 2019 | |
| Morphosys, US INC. | $18.17 | 2023 | Monjuvi |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Diamond listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.